Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects
Educational Objectives:
At the completion of this activity, participants will be able to:
Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan
He has no relevant financial relationships with commercial interests to disclose.
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit.
Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part1
This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene.